Berylson Capital Partners, LLC Adaptive Biotechnologies Corp Transaction History

Berylson Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $259,980 - $368,760	-42,000 Reduced 15.56%	228,000 $1.53 Million
Q1 2023 May 15, 2023	SELL	$7.8 - $10.11 $153,862 - $199,429	-19,726 Reduced 6.81%	270,000 $2.38 Million
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $650,000 - $1.27 Million	100,000 Added 52.71%	289,726 $2.06 Million
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $1.21 Million - $2.79 Million	189,726 New	189,726 $1.54 Million
Q4 2021 Feb 14, 2022	SELL	$25.17 - $36.85 $1.54 Million - $2.25 Million	-61,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$30.02 - $39.87 $5.56 Million - $7.38 Million	-185,200 Reduced 75.22%	61,000 $2.07 Million
Q2 2021 Aug 16, 2021	SELL	$32.22 - $44.59 $2.25 Million - $3.11 Million	-69,800 Reduced 22.09%	246,200 $10.1 Million
Q1 2021 May 17, 2021	BUY	$37.26 - $67.74 $11.8 Million - $21.4 Million	316,000 New	316,000 $12.7 Million

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Berylson Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Berylson Capital Partners, LLC with notifications on news.